Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer

Fig. 1

CDC20 was the most significantly altered E3 ligase in prostate cancer and associated with cell death and immunity A Volcano plot of the differentially expressed E3 ligases-related genes in TCGA-PRAD datasets. The Red dots show genes that have significant increases in the cancer group. Blue dots show genes that have significant decreases in the cancer group. The heatmap of the top 10 genes in A. C Heatmap of the top 10 differentially expressed E3 ligase genes in the GSE70768, GSE28680, GSE6811, and GSE2443 datasets. The expression profile of the E3 ligases-related genes was extracted from the indicated datasets and was analyzed among normal prostate, hormone-sensitive prostate cancer (HSPC), and castration-resistant prostate cancer (CRPC). D The representative images of immunohistochemistry analysis from 6 normal prostate and 102 prostate cancer tissue with various Gleason scores. The quantification of D. F The relative mRNA expression of CDC20 in prostate cancer with different Gleason scores in the Oncopression database. G A schematic graph indicating the experiment design (up). The volcano plot of the differentially expressed genes in PC3 with or without the depletion of CDC20. H, I GSEA-based GO analysis-enrichment plots of representative gene sets in prostate cancer patients with CDC20 depletion

Back to article page